Certain Common Stock of Kiora Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 1-SEP-2023. These Common Stock will be under lockup for 91 days starting from 2-JUN-2023 to 1-SEP-2023.

Details:
The Company's officers, directors, each of their respective affiliates and associated partners have agreed with the underwriters to be subject to a lock-up period of 90 days following the date of this prospectus. This means that, during the applicable lock-up period, such persons may not offer for sale, contract to sell, sell, distribute, grant any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose of, directly or indirectly, any shares of common stock or any securities convertible into, or exercisable or exchangeable for, shares of common stock. Certain limited transfers are permitted during the lock-up period if the transferee agrees to these lock-up restrictions. The company has also agreed, in the underwriting agreement, to similar lock-up restrictions on the issuance and sale of securities for 90 days following the closing of this offering, although company will be permitted to issue stock options or stock awards to directors, officers and employees under existing plans. Ladenburg Thalmann & Co. Inc. may, in their sole discretion and without notice, waive the terms of any of these lock-up agreements.